ELAN Q3 2021 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B+27.1% YoY

Gross Profit

$488M43.1% margin

Operating Income

$52M4.6% margin

Net Income

-$104M-9.2% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-11.6%

Cash Flow

Operating Cash Flow

$89M

Free Cash Flow

$64M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$16.6B

Total Liabilities

$8.9B

Stockholders' Equity

$7.7B

Cash & Equivalents

$453M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$890M	+27.1%
Gross Profit	$488M	$352M	+38.6%
Operating Income	$52M	-$14M	+482.4%
Net Income	-$104M	-$135M	+23.0%

Revenue Segments

Farm Animal

$583M52%

Pet Health

$527M47%

Contract Manufacturing

$21M2%

Geographic Segments

Non-US

$624M55%

UNITED STATES

$507M45%